• Gut Punch: Finch's Flagging Microbiome Program Folds, Leading to 95% Staff Cut

    7 days ago - By MedCity News

    Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.
    Read more ...